Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Notably, its weight-reducing efficacy in patients with common obesity is superior to that of other GLP-1 RAs [73-75]
Nausea affected 12-18% of participants at 5 mg, rising to 17-22% at higher doses
Whilst the primary therapeutic targets are appetite-regulating centres, the widespread distribution of GLP-1 receptors means that semaglutide could theoretically influence neurological functions beyond appetite control
Some people may also experience GI side effects
Looking ahead, continued progress in GLP-1R-targeted nanomedicine will depend on the integration of AI for rational design, refinement of personalized delivery systems, and robust clinical validation
US$ 29.64
US$ 23.33
US$ 28.93
US$ 24.75
